Citius Pharmaceuticals Bolsa (NASDAQ: CTXR)

Últimas noticias sobre Citius Pharmaceuticals (NASDAQ:CTXR) Bolsa

CITIUS PHARMACEUTICALS INC

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Advanced Environmental Recycling Technologies

AERT

AILE

CTXR

HONE

HSON

INTZ

KORE

LITM

NATR

PDYN

REKR

SLDP

VINC

WATT

Descubre los mayores ganadores y perdedores en el mercado previo tras movimientos impactantes en acciones clave hoy.

Las acciones de Vincerx Pharma (VINC) suben alrededor del 64%; 20 acciones que se mueven en premercado

News

Pre-Market Outlook

Markets

Trading Ideas

CCTG

LUNA

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: CVM, CCTG, LUNA, CTXR y GNS.

5 acciones en el foco este lunes: CVM, CCTG, LUNA, CTXR y GNS

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

Susquehanna analyst Charles Minervino maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $40 to $46.

Price Target

Analyst Ratings

Susquehanna Maintains Neutral on Valaris, Raises Price Target to $46

If you got a bonus at work, Kevin O'Leary wants you to pause before spending it. The investor and TV personality says the worst thing you can do is waste that money on something &#8220;frivolous and useless.&#8221;
<h2 class="wp-block-heading">O'Leary's Bonus Rule: Use It To Eliminate Debt</h2>
In a recent video <a href="https://x.com/kevinolearytv/status/1938964353320903109">posted on X</a>, O'Leary said, &#8220;The temptation is to go buy something frivolous and useless. That's a waste of money. The discipline is to do this: <a href="https://www.benzinga.com/money/best-ways-to-pay-off-credit-card-debt">Pay off your credit card debt</a>. Anything left over, knock a little bit off your mortgage.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
O'Leary&#8217;s core message is simple: Use your bonus to get rid of debt. &#8220;You want a real bonus in life? <a href="https://www.benzinga.com/personal-finance/25/02/43816145/i-dont-have-any-debt-kevin-oleary-pays-for-everything-in-cash-but-a-finance-youtuber-points-out-its-easy-to-avoid-debt-when-youre-rich">Live it debt-free</a>. That's a bonus. That's why you use your bonus to get [there],&#8221; he said.
His advice lines up with what many personal finance experts recommend when you come into extra money, whether it&#8217;s from a bonus, inheritance, <a href="https://www.benzinga.com/personal-finance/entrepreneurship/25/06/46026335/from-side-hustle-to-big-business-young-entrepreneur-makes-354000-a-month">side hustle</a> or tax refund.
<h2 class="wp-block-heading">What To Do With Extra Money</h2>
The first step is to <a href="https://www.benzinga.com/money/what-to-do-with-savings">eliminate high-interest debt</a>, especially credit card balances that can come with rates up to 27%. This is a common recommendation from personal finance experts like Dave Ramsey, who emphasize paying off debt before making any major financial moves. Investing usually won't generate returns that high, so paying off debt can be a smarter move.
Next, focus on building an emergency fund that can cover three to six months of living expenses. Stash it in a <a href="https://www.benzinga.com/money/best-high-yield-savings-accounts">high-yield savings</a> or money market account.
Trending: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
If you own a home and your mortgage rate is above 4%, <a href="https://www.benzinga.com/money/how-to-lower-your-mortgage-payment">putting extra money toward your principal</a> can reduce interest over the life of the loan and shorten your repayment timeline.
Once you&#8217;re on solid footing, consider increasing your retirement contributions, starting or adding to a health savings account, or <a href="https://www.benzinga.com/money/best-529-plans">putting money into a 529 plan</a> for education savings.
Other smart moves include <a href="https://www.benzinga.com/money/open-brokerage-account">starting a brokerage account</a>, <a href="https://www.benzinga.com/money/how-to-invest-in-real-estate">investing in real estate</a>, <a href="https://www.benzinga.com/personal-finance/24/10/41285154/mark-cuban-says-if-youre-starting-a-business-and-you-take-out-a-loan-youre-a-moron-99-of-small-b">launching a business</a>, or saving for a big future purchase.
And yes, it's perfectly fine to spend a little on yourself, just don't let that come before taking care of your financial foundation.
Still, O'Leary's bottom line remains straightforward: using your bonus to eliminate debt offers the most long-term value. &#8220;Getting rid of debt is the key thing,&#8221; he said.
Read Next:
<ul class="wp-block-list">
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Image: Shutterstock

Personal Finance

Kevin O'Leary Says If You Got A Bonus, Don't Blow It. Pay Off Your Debt, Kill Your Credit Cards, And Chase Freedom By Living Debt-Free

Susquehanna analyst Bascome Majors maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Positive and lowers the price target from $46 to $44.

Susquehanna Maintains Positive on Schlumberger, Lowers Price Target to $44

Texas Instruments's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NYSE">TXN</a>) short percent of float has fallen 12.71% since its last report. The company recently reported that it has 16.83 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Texas Instruments Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385626_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Texas Instruments has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Texas Instruments's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Texas Instruments's peer group average for short interest as a percentage of float is 5.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Texas Instruments's Recent Short Interest

SolarEdge Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NYSE">SEDG</a>) short percent of float has fallen 12.33% since its last report. The company recently reported that it has 15.92 million shares sold short, which is 31.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.65 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>SolarEdge Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SolarEdge Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SolarEdge Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, SolarEdge Technologies's peer group average for short interest as a percentage of float is 7.71%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SEDG

How Do Investors Really Feel About SolarEdge Technologies?

Blue Owl Capital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) short percent of float has risen 28.81% since its last report. The company recently reported that it has 37.75 million shares sold short, which is 6.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Blue Owl Capital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385615_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Blue Owl Capital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Blue Owl Capital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Blue Owl Capital's peer group average for short interest as a percentage of float is 3.50%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Blue Owl Capital?

Susquehanna analyst Charles Minervino maintains Oil States International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) with a Neutral and raises the price target from $4.5 to $5.5.

Susquehanna Maintains Neutral on Oil States International, Raises Price Target to $5.5

JP Morgan analyst Destiny Jackson initiates coverage on Omada Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Overweight rating and announces Price Target of $20.

Initiation

OMDA

JP Morgan Initiates Coverage On Omada Health with Overweight Rating, Announces Price Target of $20

<a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425" title="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425</a>

Biotech

General

MBIO

Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma

Mustang Bio Designated Orphan Designation Status For "an autologous ex vivo expanded cluster of differentiation 62-enriched naive and memory T-cell investigational product that has been genetically modified using a self-inactivating lentiviral vector to express an IL13Ralpha2-targeted, hinge-optimized, 4-1BB-costimulatory chimeric antigen receptor with a truncated CD19" For The Treatment Of Malignant Glioma

WIIM

HUBG

Hub Group shares are trading higher after Baird reinstated an Outperform rating on the stock and announced a price target of $44.

Susquehanna analyst Charles Minervino maintains NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) with a Positive and lowers the price target from $19 to $18.

Susquehanna Maintains Positive on NOV, Lowers Price Target to $18

Susquehanna analyst Charles Minervino maintains Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) with a Neutral and raises the price target from $25 to $30.

Susquehanna Maintains Neutral on Noble Corp, Raises Price Target to $30

Olin shares are trading higher after the company announced an expansion of its partnership with K2 Pure Solutions.

Susquehanna analyst Charles Minervino maintains Nabors Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>) with a Neutral and raises the price target from $29 to $32.

Susquehanna Maintains Neutral on Nabors Industries, Raises Price Target to $32

Susquehanna analyst Charles Minervino maintains Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) with a Positive and lowers the price target from $24 to $23.

Susquehanna Maintains Positive on Helmerich & Payne, Lowers Price Target to $23

YAAS

Youxin Technology Shares Resume Trade

Susquehanna analyst Charles Minervino maintains TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Positive and raises the price target from $35 to $40.

Susquehanna Maintains Positive on TechnipFMC, Raises Price Target to $40

The first half of 2025 has come to a close and 21 of the 30 stocks that make up the <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">Dow Jones Industrial Average Index</a> are positive year-to-date.
Despite the impressive number of stocks with a positive performance in the first six months, the index was up around 4% with several of the components posting large declines.
2025 Performance: Through the first six months of the year, two <a href="https://www.benzinga.com/topic/magnificent-seven">Magnificent Seven stocks </a>are among the 10 best in the Dow Jones Industrial Average and two are among the 10 worst in the index based on performance.
Here's a look at the 10 best Dow Jones Industrial Average stocks in the first half:
<ol class="wp-block-list">
<li>International Business Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): +34.1%</li>
<li>Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>): +23.6%</li>
<li>JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>): +20.9%</li>
<li>Boeing Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): +18.4%</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): +18.0%</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>): +17.9%</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): +17.6%</li>
<li>Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): +17.2%</li>
<li>Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): +13.6%</li>
<li>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>): +12.3%</li>
</ol>
Here are the 10 worst performing Dow Jones Industrial Average stocks in the first half:
<ol class="wp-block-list">
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>): -38.3%</li>
<li>Merck &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): -20.4%</li>
<li>Salesforce.com Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>): -18.4</li>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): -18.1%</li>
<li>Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>): -6.1%</li>
<li>Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>): -5.7%</li>
<li>Procter &amp; Gamble Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): -5.0%</li>
<li>Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): -1.1%</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): Flat</li>
<li>McDonald's Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NASDAQ">MCD</a>): +0.8%</li>
</ol>
Overall the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), which tracks the index, was up around 4% in the first half of 2025. This was a lower gain than the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, which had a 5.7% gain in the first half.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45932660/exclusive-sp-500-new-all-time-highs-again-2025">EXCLUSIVE: S&amp;P 500 To Hit New All-Time Highs Again In 2025? Majority Say Yes, 27% Predict This Range</a>
Why It's Important: Nvidia was one of the new Dow Jones components <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/12/42726598/dow-jones-2024-scoreboard-top-5-winners-losers-and-how-amazon-nvidia-could-reshape-2025">added in 2024</a> and the stock is one of the top performers in the first half of 2025. The stock replaced Intel, which was a top decliner in recent years.
The index also got rid of Walgreens, which was another poor performer in recent years. Its replacement Amazon was flat for the first half of 2025.
The new index makeup is showing strong signs of positive returns.
With 21 of the components positive year-to-date and one flat, this could mark one of the best years by the number of gainers in recent history.
In 2024, 18 of the 30 stocks were up for the full year. In 2023, 19 of the stocks in the index were up.
Perhaps most surprising is that two of the Magnificent Seven stocks rank among the worst performers in the first half of 2025, despite being part of the four Mag 7 members included in the Dow Jones Industrial Average.
Apple was the fourth-worst performer in the index for the first half, falling 18.1%. That marks a sharp reversal from its standout status as the only Dow Jones stock to rank among the top gainers in both 2023 and 2024.
Amazon ranked ninth with a flat return, as only eight of the components were down. 
The Dow Jones Industrial Average remains one of the most closely watched stock market indexes, serving as a gauge of overall market health. With only 30 stocks and a weighting based on stock price, rather than market capitalization, the index is less frequently used by some analysts and market experts than the broader S&amp;P 500 Index.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46198021/nvidia-vs-microsoft-vs-apple-which-stock-reaches-4-trillion-first">Nvidia Vs. Microsoft Vs. Apple: Which Stock Reaches $4 Trillion First?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Large Cap

Education

AAPL

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

MSFT

NVDA

Dow Jones 2025 First Half Scoreboard: Top 10 Winners, Losers — Where Do Nvidia, Apple Stock Rank?

GRAN

Trading Halt: Halt status updated at 11:50:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Contracts

Press Releases

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Earnings

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Offerings

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Small Cap

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Opinion

After Major Oncology Conference, All Eyes Turn to Industry Innovation

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTOR

ONCY

TPST

TSX:ONC

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Lexaria Bioscience

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SenesTech

Talphera

TherapeuticsMD

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Screenshot 2024-08-06 at 7.17.40 PM

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Comments

Citius Pharmaceuticals

Noticias

Últimas noticias sobre Citius Pharmaceuticals (NASDAQ:CTXR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL